EDF Health

EPA and business find much to like in Senate’s TSCA reform bill

By / Published: March 3, 2016

Richard Denison, Ph.D., is a Lead Senior Scientist.

In the last day, two news outlets, Politico (“Administration largely sides with Senate negotiators in TSCA talks”) and CQ (“On Toxic Chemical Bills, Administration Prefers Senate’s”), published articles about two letters recently issued on pending TSCA reform bills in the Senate and House. Both articles are well worth reading but are behind a paywall, so I’m providing a brief summary and links to the letters here for those without access to these Hill publications.

One letter was signed by EPA Administrator Gina McCarthy on behalf of the Administration.  It identifies provisions in each bill that EPA prefers or has concerns about, based on the Administration’s TSCA reform principles.

The other letter was drafted by the American Alliance for Innovation (AAI), a large coalition of business interests, which provides a list of its “conference priorities.”  (While it does not directly cite either bill, it identifies provisions AAI seeks to retain in or jettison from the final bill.)

These two letters are the latest in a series of comparisons of the two measures by interested parties, issued as House and Senate negotiators look to reconcile differences between them.  We have blogged previously on the preferences and concerns expressed by two groups of state authorities (links to their assessments are provided in that post).

While the documents differ with respect to the scope of issues they address, the common characteristic of all four is that each identifies significantly more provisions they prefer in the Senate bill’s more comprehensive approach, compared to House bill.

Of course the goal is to get to the best law possible. EDF is confident that legislators on both sides of the aisle, in both chambers of Congress, are working hard to reach agreement on a strong bill to send to the president. The opportunity has never been so near at hand, if Congress can just finish the job.

Posted in Health policy, TSCA reform / Tagged , | Comments are closed

“Big data” comes to chemical testing – How to ensure more is better

By / Published: February 24, 2016

Jonathan Choi is a chemicals policy fellow.

EDF Senior Scientist Dr. Jennifer McPartland contributed to this post.

The beginning of this century will no doubt be known for a lot of things. In the biological sciences, I predict it’ll be known for big data. It’s hard to wrap your head around just how far we’ve come already. For example, the data chips that sing “happy birthday” to your loved ones in those horrendously overpriced cards have more computing power than the Allies did in 1945. When I first started using computers, the 5.4” floppy disk was being replaced by the new 256Kb 3.5” disk. Now in Korea, you can get 1 GB per second internet speeds for $20 a month. That’s around 4000 floppy disks of data per second for about as much as I spend every week at the burrito place down the street.

In the biological sciences, we’ve seen an explosion of new ways to generate, collect, analyze, and store data. We’re photographing the world’s biodiversity and sharing it with crowdsourced taxonomists. We’re creating a database of the genomes of the world’s organisms. We’re mapping chemical exposures (our exposome), inventorying the microbes that live in our guts (our microbiome), ripping apart cells and sequencing every bit of messenger RNA that floats around inside (our transcriptome), and much more.

So, it’s not too surprising that regulatory agencies like EPA are pushing their own efforts to amass large quantities of data to help meet their missions. EPA has the unenviable task of reviewing tens of thousands of chemicals currently on the market with little health and safety data, on top of hundreds of new chemicals banging at its door each year. As we have written on numerous occasions, the agency clearly needs a better law that gives it greater authority to get the data it needs to effectively evaluate and manage chemical risks. But, given the information abyss in which we operate, we could definitely stand to adopt new testing approaches that generate at least screening level data on chemicals faster.   Read More »

Posted in Emerging science, Emerging testing methods, Health science / Tagged , , | Comments are closed

FDA decides 3 PFCs are unsafe: Detailed look at the decision

By Tom Neltner, Senior Director, Safer Chemicals Initiative / Published: February 11, 2016

Tom Neltner, J.D., is Chemicals Policy Director.

FDA’s decision to remove its approval of three long-chain perfluorinated compounds sets important precedents on the assessment of food ingredients, food contact substances, and chemicals used to make food.

[pullquote]

FDA concluded:

  • Class: All long-chain chemicals with at least one linear, perfluorinated chain of eight or more carbon atoms should be considered a class.
  • Data gaps: Where reproductive and developmental toxicity data are lacking for any chemical in this class, the data available for perfluorinated octanoic acid (PFOA) should be used to fill the gaps.
  • Study methods: If a chemical is biopersistent in the body, standard toxicology methods used to evaluate food additives need to be upgraded.

[/pullquote]On Jan. 4, 2016, the Food and Drug Administration (FDA) announced that it changed its regulations to remove the agency’s approval of three specific long-chain perfluorinated compounds (PFCs) as food additives. The agency approved use of these chemicals between 1967 and 1997, allowing them to be added to paper and paperboard that comes in contact with aqueous and fatty foods. Until the late 2000s, they were commonly used in pizza boxes, sandwich wrappers, and paper in frozen food packaging – virtually anywhere a food manufacturer wanted to use paper packaging that would repel oil and water.

Domestic PFC manufacturers report that these food contact substance (FCS) uses have been abandoned, although others report trace levels still appearing in paper products used for food, most likely as a result of contamination. There are reports, however, that foreign companies have begun producing PFCs. As long as these additives are officially allowed by FDA, there is a possibility that food manufacturers who are not diligent could resume their use without knowing it. The agency’s decision makes it less likely that will happen.

FDA’s decision marks the first time it has used a food additive petition to remove an approval based on safety concerns; a few years ago, it removed approvals for use of bisphenol A in infant formula packaging and baby bottles and sippy cups – but those removals were based on market abandonment, not safety. This safety-driven decision sets a precedent and serves as a roadmap for how safety decisions should be made for all additives including those considered by industry to be ‘generally recognized as safe’ (GRAS).

No longer safe – unpacking the agency’s reasoning for a class of chemicals and safety concerns Read More »

Posted in Emerging science, Emerging testing methods, FDA, Food, Health policy, Health science, PFAS, Regulation / Comments are closed

State authorities weigh in on Senate and House TSCA reform bills

By / Published: February 9, 2016

Richard Denison, Ph.D., is a Lead Senior Scientist.

In recent weeks, two documents have been released by state government officials and organizations that take a deep dive into those aspects of the Senate and House bills to reform the Toxic Substances Control Act (TSCA) most relevant to them.  The documents explicitly point to specific provisions in one or both bills that are preferred or opposed.

The bills the documents compare are the Frank R. Lautenberg Chemical Safety for the 21st Century Act (S. 697), passed by the full Senate on December 17, 2015; and the TSCA Modernization Act of 2015 (H.R. 2576), passed by the House of Representatives on June 23, 2015.

Here are the documents:

  • Environmental Council of the States (ECOS): An 11-page table dated January 7, 2016 posted in the “Featured” section of ECOS’ home page provides a side-by-side comparison of the two bills, focused mainly but not exclusively on state-federal relationship issues.  (Note that the preamble to the table indicates it does not represent a formal consensus, and many of the indications of preferences begin with a qualifier such as “Many states believe … .”)
  • 12 State AGs letter: A 7-page letter dated January 19, 2016 signed by the Attorneys General of 12 states (MA, CA, HI, IA, ME, MD, NH, NY, OR, RI, VT and WA) to the relevant Senate and House committee Chairmen and Ranking Members sets forth principles for state-federal relationships under TSCA reform and provides recommendations for reconciling those provisions of the Senate and House bills.

Both documents are well worth reading in their entireties.  To help me understand them, I have developed the table below that lists each specific provision identified in these documents for which a preference or opposition has been expressed or is readily discernible with respect to the Senate or House bill.   Read More »

Posted in Health policy, TSCA reform / Tagged , , | Authors: / Comments are closed

EPA simply must do better on transparency and chemical data access

By / Published: February 2, 2016

Richard Denison, Ph.D., is a Lead Senior Scientist.  Lindsay McCormick is a Research Analyst.

[This is Part Two of a two-part series.  Here is a link to Part One.]

Under this Administration, EPA has taken some significant steps toward reversing decades of passivity and secretive practices that evolved under the Toxic Substances Control Act (TSCA) when it came to transparency in decision-making and providing access to chemical information it obtains or develops.

Several initiatives undertaken through what EPA originally termed its enhanced chemicals management program have developed and laid out clearer policies and procedures in areas such as:  chemical prioritization (leading to its Work Plan Chemicals Program); enforcing limits on and reviewing confidential business information (CBI) claims asserted by industry (leading to its declassification of hundreds of previously hidden chemical identities and health and safety studies that companies had illegitimately claimed confidential or no longer merited protection from disclosure, but that EPA had not bothered to review or challenge before now); and EPA’s regulatory efforts to reduce risks from exposures to toxic chemicals (leading to its Action Plans on high-concern chemicals and proposed follow-up activities for work plan chemicals where assessments – the first completed in decades – have identified significant risks).

EPA has also developed new databases and tools to provide greater access to chemical information in its possession and regulatory decisions and supporting documents it develops; these include the Chemical Data Access Tool and ChemView.

All of these efforts are still very much works in progress but hold significant potential to improve transparency, information access and risk reduction.

But sometimes the Agency does something that makes clear just how far it still has to go in these respects.  Unfortunately, a case in point is its recent effort toward assessing risks of a cluster of flame retardant chemicals, the brominated phthalates, some of which are in wide use and are showing up in everything from house dust to dolphins.   Read More »

Posted in Health policy / Tagged , , , , , | Comments are closed

Very little, very late: EPA still lacks data on safety of widely used flame retardant chemicals

By Lindsay McCormick / Published: February 1, 2016

Lindsay McCormick is a Research Analyst.  Richard Denison, Ph.D., is a Lead Senior Scientist.

[This is Part One of a two-part series.  Here is a link to Part Two.]

Last summer, EPA released a Problem Formulation and Data Needs Assessment describing the inadequacy of data available to conduct risk assessments on a group of brominated phthalate flame retardants – two of which are major components in widely used Firemaster products. 

This is the first of two blog posts on the comments EDF recently submitted to EPA on this document.  In this post, we discuss the growing public health and environmental concerns over use of Firemaster products and the recommendations we made to EPA on steps it needs to promptly take to address these concerns.  In our second post, we’ll lay out our serious concerns about the lack of transparency, limited data access, and allowance of unwarranted confidentiality claims that our review of EPA’s document brought to light.

 

First, a brief history

In the mid-2000s, Great Lakes Chemicals Corporation (now Chemtura) agreed to phase out production of polybrominated diphenyl ether (PBDE) flame retardants due to mounting evidence of their health effects and their persistence and accumulation in people and the environment.  Soon after, the use of the company’s replacement Firemaster products skyrocketed.

The two main components of Firemaster products, 2-Ethylhexyl 2,3,4,5- tetrabromobenzoate (TBB) and bis(2-Ethylhexyl) -3,4,5,6- tetrabromophthalate (TBPH), are  high production volume (“HPV”) chemicals – each produced at more than one million pounds annually.

Unfortunately, use of these chemicals rose to such levels – replacing PBDEs in consumer products like polyurethane foam-based furniture and electronics – without sufficient data and review to establish their safety.   Read More »

Posted in Emerging science, Health policy, Health science / Tagged , , , , | Comments are closed